Arlauckas, Sean P.

TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy

Rodell, C. B., Arlauckas, S. P., Cuccarese, M. F., Garris, C. S., Li, R., Ahmed, M. S., Kohler, R. H., Pittet, M. J., & Weissleder, R. (2018) · Nature Biomedical Engineering

Immune cells in cancerImmunotherapy and Immune Responses

Cited by 1,099

Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12

Garris, C. S., Arlauckas, S. P., Kohler, R. H., Trefny, M. P., Garren, S., Piot, C., Engblom, C., Pfirschke, C., Siwicki, M., Gungabeesoon, J., et al. (2018) · Immunity

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 966

In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy

Arlauckas, S. P., Garris, C. S., Kohler, R. H., Kitaoka, M., Cuccarese, M. F., Yang, K. S., Miller, M. A., Carlson, J. C., Freeman, G. J., Anthony, R. M., et al. (2017) · Science Translational Medicine

Cancer Immunotherapy and BiomarkersImmune cells in cancer

Cited by 669

Prediction of anti-cancer nanotherapy efficacy by imaging

Miller, M. A., Arlauckas, S., & Weissleder, R. (2017) · Nanotheranostics

Nanoparticle-Based Drug DeliveryNanoplatforms for cancer theranostics

Cited by 74